Sang Yun Hwang1,2, Sanjay Warrier1,2, Stephen Thompson1,3,4, Trent Davidson1,4,5, Jia Lin Yang1,4, Philip Crowe1,3,4. 1. Prince of Wales Hospital Clinical School, University of New South Wales, Sydney, New South Wales, Australia. 2. Department of Surgery, Prince of Wales Hospital, Sydney, New South Wales, Australia. 3. Department of Radiation Oncology, Prince of Wales Hospital, Sydney, New South Wales, Australia. 4. Sydney Sarcoma Unit, Prince of Wales Hospital, Sydney, New South Wales, Australia. 5. Department of Anatomical Pathology, South Eastern Sydney Laboratory Services, Prince of Wales Hospital, Sydney, New South Wales, Australia.
Abstract
AIM: Retroperitoneal sarcomas (RPSs) are large, rare tumors. The role of core biopsy for retroperitoneal masses identified by preoperative imaging is unclear and we report the safety and accuracy of core biopsies at a specialized sarcoma unit in Sydney, Australia. METHODS: A retrospective analysis of a prospectively collected database was performed to identify the safety and accuracy of core biopsies in patients who were confirmed to have RPS. RESULTS: Twenty-two patients underwent biopsies with no recorded morbidity or tumor seeding. RPS was correctly identified in 82%. Median follow-up was 19 months. CONCLUSION: We demonstrate that core biopsy is safe and can identify RPSs.
AIM: Retroperitoneal sarcomas (RPSs) are large, rare tumors. The role of core biopsy for retroperitoneal masses identified by preoperative imaging is unclear and we report the safety and accuracy of core biopsies at a specialized sarcoma unit in Sydney, Australia. METHODS: A retrospective analysis of a prospectively collected database was performed to identify the safety and accuracy of core biopsies in patients who were confirmed to have RPS. RESULTS: Twenty-two patients underwent biopsies with no recorded morbidity or tumor seeding. RPS was correctly identified in 82%. Median follow-up was 19 months. CONCLUSION: We demonstrate that core biopsy is safe and can identify RPSs.